Recent Updates
Recently added Catalysts
KRYS

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

Key Takeaway: PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4. Kri
Price reaction · baseline $70.9 (2022-09-28 close) · hit after-hours · clean, no other KRYS news in the window
day 0 close
-0.5%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+100%
120-day peak, hindsight
Typical move
4.2%
average across 5 past catalysts
Lead asset
KB707
Phase 1 · Cancer

Full Press Release Details

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6th Annual Genetic Medicines Conference in New York from October 3-4.
Krish Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor meetings on October 4.
A webcast of the presentation will be available here beginning at 9:00am ET on Tuesday, October 4 and will be posted on the Investor section of the Company’s website.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
Source: Krystal Biotech, Inc.
Last updated: Sep 29, 2022